Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4810 - Prognostic factors in patients with advanced biliary tract cancer (BTC) who showed durable disease control with first-line gemcitabine plus cisplatin (GemCis)

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cytotoxic Therapy

Tumour Site

Hepatobiliary Cancers

Presenters

Jaewon Hyung

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

J. Hyung1, C. Yoo1, K. Kim2, B.J. Kim3, J.H. Jeong2, H. Chang1, B. Ryoo1

Author affiliations

  • 1 Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR
  • 2 Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 3 Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul/KR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4810

Background

GemCis is the standard first-line chemotherapy for patients with advanced BTC. In ABC-02 study, the BTC patients received up to 6-8 cycles of three-weekly GemCis. Currently, treatment strategy and prognostic factors of patients without progression to first-line GemCis is not well defined.

Methods

Advanced BTC patients treated with GemCis between April 2010 and February 2016 at Asan Medical Center, Seoul, Korea, were retrospectively analyzed. The patients without progression after 6-8 cycles were included in the study. Univariate and multivariate analyses were performed to identify prognostic factors for overall survival (OS).

Results

Among the 740 BTC patients in the initial screen, 231 cases (31.2%) were eligible for analysis. Median follow-up period was 23.8 months [IQR 5.1-86.3 months], the median OS from the initiation of treatment was 22.3 months [95% CI 19.0-25.7], and the median PFS was 12.5 months [95% CI 11.1-13.9]. Median age was 60 year-old (29-77) and 211 patients (91.3%) had ECOG performance status of 0 or 1 at the time of diagnosis. Objective response was achieved in 49 patients (21.2%). OS was significantly associated with number of metastatic site (>2 vs < 2: Hazard ratio [HR]=1.5, 95% CI 1.0-2.3, p = 0.04), best response to GemCis (stable disease vs partial response: HR = 1.9, 95% CI 1.3-2.7, p = 0.006). Maintenance therapy after durable disease control after at least 6 cycles of GemCis was not associated with OS (p = 0.47).

Conclusions

In patients who showed durable disease control to first-line GemCis, number of metastatic sites and objective response were significant poor prognostic factors. These results might help to design future clinical trials for this patient population.

Clinical trial identification

Legal entity responsible for the study

Changhoon Yoo.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.